RT Journal Article
SR Electronic
T1 Co-expression-wide association studies link genetically regulated interactions with complex traits
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.02.24314813
DO 10.1101/2024.10.02.24314813
A1 Malakhov, Mykhaylo M.
A1 Pan, Wei
YR 2024
UL http://medrxiv.org/content/early/2024/12/13/2024.10.02.24314813.abstract
AB Transcriptome- and proteome-wide association studies (TWAS/PWAS) have proven successful in prioritizing genes and proteins whose genetically regulated expression modulates disease risk, but they ignore potential co-expression and interaction effects. To address this limitation, we introduce the co-expression-wide association study (COWAS) method, which can identify pairs of genes or proteins whose genetically regulated co-expression is associated with complex traits. COWAS first trains models to predict expression and co-expression conditional on genetic variation, and then tests for association between imputed co-expression and the trait of interest while also accounting for direct effects from each exposure. We applied our method to plasma proteomic concentrations from the UK Biobank, identifying dozens of interacting protein pairs associated with cholesterol levels, Alzheimer’s disease, and Parkinson’s disease. Notably, our results demonstrate that co-expression between proteins may affect complex traits even if neither protein is detected to influence the trait when considered on its own. We also show how COWAS can help disentangle direct and interaction effects, providing a richer picture of the molecular networks that mediate genetic effects on disease outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health (NIH) under grants R01 AG065636 and RF1 AG067924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors also acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing high-performance computing resources that contributed to the research results reported within this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Genotype, covariate, and protein expression data from the UK Biobank are available through the UK Biobank data access process (https://www.ukbiobank.ac.uk/enable-your-research). Access to the UK Biobank data was approved through UK Biobank Application #35107. Annotations for proteins assayed by the UK Biobank Pharma Proteomics Project are publicly available on Synapse (https://www.synapse.org/Synapse:syn51364943). Protein pairs with known interactions are publicly accessible in the HIPPIE web tool (https://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie). Publicly available GWAS summary statistics for cholesterol levels were downloaded from the Global Lipids Genetics Consortium website (https://csg.sph.umich.edu/willer/public/glgc-lipids2021). Publicly available GWAS summary statistics for Alzheimer's disease and Parkinson's disease were obtained from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas) under accession numbers GCST90027158 and GCST009325, respectively.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenotype, covariate, and protein expression data from the UK Biobank are available through the UK Biobank data access process (https://www.ukbiobank.ac.uk/enable-your-research). Access to the UK Biobank data was approved through UK Biobank Application #35107. Annotations for proteins assayed by the UK Biobank Pharma Proteomics Project are publicly available on Synapse (https://www.synapse.org/Synapse:syn51364943). Protein pairs with known interactions are publicly accessible in the HIPPIE web tool (https://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie). Publicly available GWAS summary statistics for cholesterol levels were downloaded from the Global Lipids Genetics Consortium website (https://csg.sph.umich.edu/willer/public/glgc-lipids2021). Publicly available GWAS summary statistics for Alzheimer’s disease and Parkinson’s disease were obtained from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas) under accession numbers GCST90027158 and GCST009325, respectively.